Actos

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

pioglitazone hydrochloride

Disponibbli minn:

CHEPLAPHARM Arzneimittel GmbH

Kodiċi ATC:

A10BG03

INN (Isem Internazzjonali):

pioglitazone

Grupp terapewtiku:

Drugs used in diabetes

Żona terapewtika:

Diabetes Mellitus, Type 2

Indikazzjonijiet terapewtiċi:

Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

Sommarju tal-prodott:

Revision: 30

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2000-10-13

Fuljett ta 'informazzjoni

                                28
B. PACKAGE LEAFLET
29
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ACTOS 15 MG TABLETS
ACTOS 30 MG TABLETS
ACTOS 45 MG TABLETS
pioglitazone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Actos is and what it is used for
2.
What you need to know before you take Actos
3.
How to take Actos
4.
Possible side effects
5.
How to store Actos
6.
Contents of the pack and other information
1.
WHAT ACTOS IS AND WHAT IT IS USED FOR
Actos contains pioglitazone. It is an anti-diabetic medicine used to
treat type 2 (non-insulin dependent)
diabetes mellitus in adults, when metformin is not suitable or has
failed to work adequately. This is the
diabetes that usually develops in adulthood.
Actos helps control the level of sugar in your blood when you have
type 2 diabetes by helping your
body make better use of the insulin it produces. Your doctor will
check whether Actos is working 3 to
6 months after you start taking it.
Actos may be used on its own in patients who are unable to take
metformin, and where treatment with
diet and exercise has failed to control blood sugar or may be added to
other therapies (such as
metformin, sulphonylurea or insulin) which have failed to provide
sufficient control of blood sugar.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ACTOS
DO NOT TAKE ACTOS
-
if you are allergic to pioglitazone or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have heart failure or have had heart failure in the past.
-
if you have liver disease.
-
if you have had diabetic ketoa
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Actos 15 mg tablets
Actos 30 mg tablets
Actos 45 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Actos 15 mg tablets
Each tablet contains 15 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 92.87 mg of lactose monohydrate (see section
4.4).
Actos 30 mg tablets
Each tablet contains 30 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 76.34 mg of lactose monohydrate (see section
4.4).
Actos 45 mg tablets
Each tablet contains 45 mg of pioglitazone (as hydrochloride).
_Excipient with known effect_
Each tablet contains 114.51 mg of lactose monohydrate (see section
4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Actos 15 mg tablets
The tablets are white to off-white, round, convex and marked ‘15’
on one face and ‘ACTOS’ on the
other face.
Actos 30 mg tablets
The tablets are white to off-white, round, flat and marked ‘30’ on
one face and ‘ACTOS’ on the other
face.
Actos 45 mg tablets
The tablets are white to off-white, round, flat and marked ‘45’ on
one face and ‘ACTOS’ on the other
face.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pioglitazone is indicated as second or third line treatment of type 2
diabetes mellitus as described
below:
3
as
MONOTHERAPY
-
in adult patients (particularly overweight patients) inadequately
controlled by diet and
exercise for whom metformin is inappropriate because of
contraindications or
intolerance
as
DUAL ORAL THERAPY
in combination with
-
metformin, in adult patients (particularly overweight patients) with
insufficient
glycaemic control despite maximal tolerated dose of monotherapy with
metformin
-
a sulphonylurea, only in adult patients who show intolerance to
metformin or for
whom metformin is contraindicated, with insufficient glycaemic control
despite
maximal tolerated dose of monotherapy with a sulphonylurea.
as
TRIPLE ORAL THERAPY
in combination 
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 28-08-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 29-09-2016
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 28-08-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 28-08-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 28-08-2023

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti